Journal Information
Vol. 19. Issue 4.
Pages 215-222 (April 2023)
Share
Share
Download PDF
More article options
ePub
Visits
...
Vol. 19. Issue 4.
Pages 215-222 (April 2023)
Review Article
Rheumatological adverse events secondary to immune checkpoint inhibitors
Eventos adversos reumatológicos secundarios al uso de inhibidores de punto de control inmunitario
María Cecilia Garbarinoa,b,
Corresponding author
garbarinomc@gmail.com

Corresponding author.
, Natalia Manzanoc, Osvaldo Messinab, Marcelo Zylbermana,c
a Departamento de Medicina Interna, Hospital General de Agudos «Dr. Cosme Argerich», Buenos Aires, Argentina
b Sección Reumatología, Hospital General de Agudos «Dr. Cosme Argerich», Buenos Aires, Argentina
c Departamento de Medicina Interna, Instituto Alexander Fleming, Buenos Aires, Argentina
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Abstract

The first experiences with a group of drugs called immune checkpoint inhibitors for the treatment of cancer were described in 2010. They are currently used in many tumours, with successful survival outcomes but a new profile of adverse events. This new spectrum of immune-mediated toxicities includes an exaggerated inflammatory response of T lymphocyte and the development of autoimmune diseases or similar pathologies. Of these, of particular note are the rheumatological toxicities. This review aims to alert internists and rheumatologists to their recognition and clinical management.

Keywords:
Cancer immunotherapy
Immune checkpoint inhibitors
Musculoskeletal
Arthritis
Myositis
Resumen

En 2010 se conocieron las primeras experiencias con un grupo de medicamentos denominados inhibidores de los puntos de control inmunitario (IPCI) para el tratamiento del cáncer. Actualmente, se utilizan en diferentes tumores y estadios, modificando la sobrevida de los pacientes, pero generando un nuevo perfil de toxicidad. Este nuevo espectro de toxicidades inmunomediadas (irAE) son generadas por una exagerada respuesta inflamatoria de linfocitos T que puede desarrollar enfermedades autoinmunes o patologías similares. Entre ellas, se hallan las toxicidades reumatológicas. Esta revisión se propone alertar a los internistas y reumatólogos a reconocer las irAE reumatológicas y conocer su manejo clínico.

Palabras clave:
Inmunoterapia en cáncer
Inhibidores de punto de control inmunitario
Musculoesquelético
Artritis
Miositis

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?